Top

Published in:

01-07-2016 | Mini-review

Glucagon action in the brain

Authors: Mona A. Abraham, Tony K. T. Lam

Published in: Diabetologia | Issue 7/2016

Abstract

In recent years, novel discoveries have reshaped our understanding of the biology of brain glucagon in the regulation of peripheral homeostasis. Here we compare and contrast brain glucagon action in feeding vs glucose regulation and depict the physiological relevance of brain glucagon by reviewing their actions in two key regions of the central nervous system: the mediobasal hypothalamus and the dorsal vagal complex. These novel findings pave the way to future therapeutic strategies aimed at enhancing brain glucagon action for the treatment of diabetes and obesity. This review summarises a presentation given at the ‘Novel data on glucagon’ symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Young Lee and colleagues, DOI: 10.1007/s00125-016-3965-9), and by Russell Miller and Morris Birnbaum, DOI: 10.1007/s00125-016-3955-y) and an overview by the Session Chair, Isabel Valverde (DOI: 10.1007/s00125-016-3946-z).

Hoosein NM, Gurd RS (1984) Identification of glucagon receptors in rat brain. Proc Natl Acad Sci U S A 81:4368–4372CrossRefPubMedPubMedCentral

Banks WA, Kastin AJ (1985) Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 15:287–292CrossRefPubMed

Sasaki H, Ebitani I, Tominaga M, Yamatani K, Yawata Y, Hara M (1980) Glucagon-like substance in the canine brain. Endocrinol Jpn 27(Suppl 1):135–140CrossRefPubMed

Wetsel WC, Eraly SA, Whyte DB, Mellon PL (1993) Regulation of gonadotropin-releasing hormone by protein kinase-A and -C in immortalized hypothalamic neurons. Endocrinology 132:2360–2370PubMed

Marubashi S, Tominaga M, Katagiri T et al (1985) Hyperglycaemic effect of glucagon administered intracerebroventricularly in the rat. Acta Endocrinol (Copenh) 108:6–10

Honda K, Kamisoyama H, Uemura T et al (2012) The mechanism underlying the central glucagon-induced hyperglycemia and anorexia in chicks. Comp Biochem Physiol A Mol Integr Physiol 163:260–264CrossRefPubMed

Amir S (1986) Central glucagon-induced hyperglycemia is mediated by combined activation of the adrenal medulla and sympathetic nerve endings. Physiol Behav 37:563–566CrossRefPubMed

Agarwala GC, Bapat SK (1977) Effect of centrally administered glucagon on blood glucose levels in dogs. Indian J Med Res 66:323–330PubMed

Agarwala GC, Mishra R, Jaiswal G, Bapat V (1989) Effect of centrally administered glucagon on liver glycogen & enzymes in anaesthetised dogs. Indian J Med Res 90:372–378PubMed

10.

Mighiu PI, Yue JT, Filippi BM et al (2013) Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med 19:766–772CrossRefPubMed

11.

Abraham MA, Yue JT, LaPierre MP et al (2014) Hypothalamic glucagon signals through the KATP channels to regulate glucose production. Mol Metab 3:202–208CrossRefPubMed

12.

Inokuchi A, Oomura Y, Nishimura H (1984) Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiol Behav 33:397–400CrossRefPubMed

13.

Honda K, Kamisoyama H, Saito N, Kurose Y, Sugahara K, Hasegawa S (2007) Central administration of glucagon suppresses food intake in chicks. Neurosci Lett 416:198–201CrossRefPubMed

14.

Kurose Y, Kamisoyama H, Honda K et al (2009) Effects of central administration of glucagon on feed intake and endocrine responses in sheep. Anim Sci J 80:686–690CrossRefPubMed

15.

Quiñones M, Al-Massadi O, Gallego R et al (2015) Hypothalamic CaMKKβ mediates glucagon anorectic effect and its diet-induced resistance. Mol Metab 4:961–970

16.

Könner AC, Janoschek R, Plum L et al (2007) Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab 5:438–449CrossRefPubMed

17.

Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V (1992) Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 262:R975–R980PubMed

18.

Bomboy JD Jr, Lewis SB, Lacy WW, Sinclair-Smith BC, Liljenquist JE (1977) Transient stimulatory effect of sustained hyperglucagonemia on splanchnic glucose production in normal and diabetic man. Diabetes 26:177–184CrossRefPubMed

19.

Felig P, Wahren J, Hendler R (1976) Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J Clin Invest 58:761–765CrossRefPubMedPubMedCentral

20.

Eigler N, Sacca L, Sherwin RS (1979) Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: a model for stress-induced hyperglycemia. J Clin Invest 63:114–123CrossRefPubMedPubMedCentral

21.

Abraham MA, Filippi BM, Kang GM, Kim MS, Lam TK (2014) Insulin action in the hypothalamus and dorsal vagal complex. Exp Physiol 99:1104–1109CrossRefPubMed

22.

Filippi BM, Yang CS, Tang C, Lam TK (2012) Insulin activates Erk1/2 signaling in the dorsal vagal complex to inhibit glucose production. Cell Metab 16:500–510CrossRefPubMed

23.

Filippi BM, Bassiri A, Abraham MA, Duca FA, Yue JT, Lam TK (2014) Insulin signals through the dorsal vagal complex to regulate energy balance. Diabetes 63:892–899CrossRefPubMed

24.

Hayes MR, Skibicka KP, Grill HJ (2008) Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149:4059–4068CrossRefPubMedPubMedCentral

25.

Hayes MR, Bradley L, Grill HJ (2009) Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150:2654–2659CrossRefPubMedPubMedCentral

26.

Hayes MR, Skibicka KP, Leichner TM et al (2010) Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation. Cell Metab 11:77–83CrossRefPubMedPubMedCentral

27.

Hansen LH, Abrahamsen N, Nishimura E (1995) Glucagon receptor mRNA distribution in rat tissues. Peptides 16:1163–1166CrossRefPubMed

28.

Parker JA, McCullough KA, Field BC et al (2013) Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes (Lond) 37:1391–1398CrossRef

29.

LaPierre MP, Abraham MA, Yue JT, Filippi BM, Lam TK (2015) Glucagon signalling in the dorsal vagal complex is sufficient and necessary for high-protein feeding to regulate glucose homeostasis in vivo. EMBO Rep 16:1299–1307CrossRefPubMed

30.

Calbet JA, MacLean DA (2002) Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. J Nutr 132:2174–2182PubMed

31.

Claessens M, Calame W, Siemensma AD, van Baak MA, Saris WH (2009) The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects. Eur J Clin Nutr 63:48–56CrossRefPubMed

32.

Day JL, Johansen K, Ganda OP, Soeldner JS, Gleason RE, Midgley W (1978) Factors governing insulin and glucagon responses during normal meals. Clin Endocrinol (Oxf) 9:443–454CrossRef

33.

Peret J, Foustock S, Chanez M, Bois-Joyeux B, Assan R (1981) Plasma glucagon and insulin concentrations and hepatic phosphoenolpyruvate carboxykinase and pyruvate kinase activities during and upon adaptation of rats to a high protein diet. J Nutr 111:1173–1184PubMed

34.

Cheung GW, Kokorovic A, Lam CK, Chari M, Lam TK (2009) Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab 10:99–109CrossRefPubMed

35.

Wang PY, Caspi L, Lam CK et al (2008) Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452:1012–1016CrossRefPubMed

36.

Weigle DS, Breen PA, Matthys CC et al (2005) A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations. Am J Clin Nutr 82:41–48PubMed

37.

Blouet C, Mariotti F, Azzout-Marniche D et al (2006) The reduced energy intake of rats fed a high-protein low-carbohydrate diet explains the lower fat deposition, but macronutrient substitution accounts for the improved glycemic control. J Nutr 136:1849–1854PubMed

38.

Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36CrossRefPubMed

39.

Pocai A, Carrington PE, Adams JR et al (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:2258–2266CrossRefPubMedPubMedCentral

40.

Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749–757CrossRefPubMed

Title: Glucagon action in the brain
Authors: Mona A. Abraham
Tony K. T. Lam
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 7/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-3950-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Glucagon action in the brain

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

An overview of glucagon research

Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Prospective study on microangiopathy in type 2 diabetic foot ulcer

Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page